Specialized expertise combined with high patient volumes drive superior results at Mayo Clinic. In a typical year, nearly 9,000 patients with a diagnosis of lymphoma receive care of any kind at Mayo Clinic.* Annually, we newly diagnose over 450 patients and provide some first line treatment or decision-making for over 700 lymphoma patients.

In a typical year, patients from more than 30 countries and more than 50 U.S. states and territories receive care for lymphoma at Mayo Clinic.†

Mayo Clinic in Rochester, Minnesota, Phoenix and Scottsdale, Arizona, and Jacksonville, Florida, annually:

*Primary reason for visit may be unrelated to lymphoma.

†Office visit for lymphoma.

Patient satisfaction with Mayo Clinic is very high.

Among patients with an outpatient office visit and a diagnosis of lymphoma at Mayo Clinic, 99% of respondents gave Mayo Clinic the top or next-to-top rating when it came to reporting on overall satisfaction with care and likelihood of recommending Mayo Clinic.

Note: Patient experience surveys administered by Press Ganey

‡Claims-based diagnosis of lymphoma accompanying 2019 office visit at Mayo Clinic in Rochester, Minnesota, Phoenix and Scottsdale, Arizona, and Jacksonville, Florida.

Patients who travel to Mayo Clinic have access to our wide range of care options, including peripheral blood stem cell transplant, chemotherapy, radiation therapy, chimeric antigen receptor (CAR-T) cell therapy and other standard therapies. Our diagnostic and interventional radiology practices use cutting-edge technology, such as positron emission tomography (PET) imaging using computerized tomography (CT) and magnetic resonance (MRI) and the development of new PET agents; the availability of 7-tesla MRI with advances in central nervous system (CNS) and bone marrow imaging; world-leading radiation dose reduction for CT; state-of-the-art expertise in procedures such as percutaneous biopsy, percutaneous ablation, central venous access, chemoembolization and other procedures; and world-leading clinical theranostics and the development and research of novel theranostics agents.

In a typical year, patients have access to dozens of clinical trials in lymphoma, which span from newly diagnosed to relapsed and refractory lymphomas in over 100 different histologies. Our care providers have played key roles in the Food and Drug Administration (FDA) approval of numerous drugs, including rituximab, ibritumomab tiuxetin, brentuximab vedotin, nivolumab, lenalidomide, plerixafor, chimeric antigen receptor (CAR-T) cell therapy and tafasitamab-cxix and lenalidomide.

Mayo Clinic has multiple physicians and scientists with research programs dedicated to lymphoma research, along with numerous clinical research associates, who together are leaders in both hematology and epidemiology lymphoma research. We are on the leading edge of discovery and hold numerous active grants and federal subawards dedicated to the continued improvement in lymphoma treatment. The Lymphoma Specialized Program of Research Excellence (SPORE) grant that Mayo Clinic collaboratively conducts with the University of Iowa has been funded continuously since 2002. We are leaders in developing patient-directed prognostic tools and clinical outcome assessments that are now used worldwide in research and clinical settings. Mayo Clinic maintains lymphoma databases that capture pathology data on patients who are eligible for research and capture long-term follow-up on consenting participants, which allows us to be international leaders in lymphoma research and care. Patients who are interested have the opportunity to participate in research, while all patients benefit from the valuable discovery and advancements in lymphoma care that Mayo Clinic continues to make.

Mayo Clinic offers remote capability to monitor your case through eConsults with your local providers and telemedicine to your home. Mayo Clinic in Rochester, Minnesota, Phoenix and Scottsdale, Arizona, and Jacksonville, Florida, conducted over 34,000 virtual visits in January 2021 alone. Carry our expertise with you throughout your journey.